Three Blends, Side by Side

The short version

This page lines up Wolverine, KLOW and GLOW on the dimensions that matter most when reading research-peptide blends: which constituents each contains, where those constituents have been studied, how strong the evidence is, the administration routes used in research, each blend's regulatory standing, and its single most important caution. The headline is simple: all three blends are built from the same small pool of constituent peptides (BPC-157, TB-500, GHK-Cu, and in the case of KLOW, KPV), and none of the three has ever been tested as a combination in any controlled study. The evidence behind each blend is the sum of single-component literatures — largely preclinical — extrapolated into a combination rationale. None is an approved medicine, and none is presented here with a human dose.

The comparison matrix

Constituent overlap

The three blends are built from the same small constituent pool. BPC-157 and TB-500 appear in all three, which is why Wolverine's published constituent evidence flows into both KLOW and GLOW. GHK-Cu appears in both KLOW and GLOW but not in Wolverine, giving those two blends a matrix-remodeling and skin-signal arm that Wolverine lacks. KPV is exclusive to KLOW, adding the PepT1-mediated anti-inflammatory NF-kB-suppression arm that the other two do not carry ^[11].

This overlap matters for reading the literature: a finding for BPC-157's angiogenic mechanism ^[4] is relevant to all three blends; a finding for GHK-Cu's collagen-stimulating properties ^[10] applies to KLOW and GLOW but not Wolverine; and KPV's gut-inflammation data ^[11] is uniquely informative about KLOW alone.

Evidence base (model)

No controlled study exists for any of the three blends. The evidence for each is the sum of its single-component literatures.

BPC-157 has the deepest individual animal record — decades of rodent work — plus three small human pilots; a 2025 systematic review classified the human evidence as Level IV-V ^[2]. TB-500's strongest human data used full-length thymosin beta-4, not the marketed seven-amino-acid fragment, so that evidence does not automatically transfer ^[5]. GHK-Cu has the most human data — but chiefly in topical dermatology, not as an injected blend component ^[10]. KPV has no human clinical trials at all ^[11].

Across all three blends, the 2026 Sports Medicine review that covers both BPC-157 and TB-500 / thymosin beta-4 provides the most honest aggregate anchor: animal-model promise, scarce human safety data, potential for serious harm, and a gray market largely outside regulatory oversight ^[1].

Administration studied

Routes in the constituent literature track the underlying research questions. BPC-157 has been studied intramuscularly, intragastrically, in drinking water, and in a tiny intravenous human safety pilot ^[3]. Thymosin beta-4 was studied intravenously in the full-length human Phase 1 study; animal thymosin beta-4 work typically used intraperitoneal dosing ^[5]. GHK-Cu's documented human evidence is topical — applied to the skin surface — with ex vivo penetration measurements characterizing how much copper crosses the dermis ^[10]. KPV's research is dominated by oral and PepT1-targeted nanoparticle delivery in mouse colitis models ^[11].

Notably, community administration of these blends (typically subcutaneous injection) has never been the route characterized in any controlled human study for any constituent, and has no validated pharmacokinetic basis for the combinations.

Regulatory and WADA status

None of the three blends is an approved drug product anywhere. BPC-157 and TB-500 are both explicitly prohibited in sport by WADA: BPC-157 under S0 (non-approved substances), and thymosin beta-4 / TB-500 under S2 (peptide hormones, growth factors, and related substances), banned at all times both in and out of competition ^[1]. GHK-Cu is legally sold as a topical cosmetic ingredient (Copper Tripeptide-1), but injectable or systemic GHK-Cu is unapproved and research-only. KPV is not specifically WADA-listed but as a non-approved peptide should be treated cautiously in any sport context.

For all three blends, the FDA has not approved any combination product, and the constituent peptides are distributed through unregulated research-supply channels.

Key caution

Each blend shares one overarching caution — no controlled combination study exists — and each has a constituent-specific dimension.

For Wolverine, the defining concern is the fragment-versus-full-protein identity gap: most of the TB-500 arm's reputation rests on full-length thymosin beta-4 data, and it is not established that the seven-amino-acid fragment reproduces those effects ^[5]. The entire synergy claim is mechanistic extrapolation from two independently studied peptides ^[2].

For KLOW, the defining structural concern is the pharmacokinetic mismatch: BPC-157 clears in under 30 minutes, the tripeptides (KPV, GHK-Cu) faster still, and the TB-500 fragment has different kinetics from the full protein — so a single co-formulated vial cannot hold all four at matched exposures. No safety or PK data exist for the combination ^[1].

For GLOW, the key tension is between GHK-Cu's meaningful human topical evidence and the absence of any injectable or combined human data for the three-peptide blend. The 2025 narrative review of BPC-157 classifies the weakest-studied constituent as investigational; the blend cannot be better evidenced than its worst-supported part ^[3].